Track topics on Twitter Track topics that are important to you
Published on BioPortfolio: 2014-10-16T19:33:30-0400
The purpose of this study is to evaluate whether rAHF-PFM is effective and safe in the treatment of hemophilia A patients who have not been treated with factor VIII before.
The purpose of this study is to compare the safety and efficacy of continuous infusion versus intermittent bolus infusion employing rAHF-PFM, a recombinant antihemophilic factor manufactur...
The purpose of this study is to determine the pharmacokinetics and safety of rAHF-PFM reconstituted in 2 mL sterile water for injection (SWFI) and compare with those of rAHF-PFM reconstitu...
The purpose of this study is to evaluate whether rAHF-PFM is safe and effective in the treatment of hemophilia A patients undergoing surgery.
The purpose of this study is to evaluate whether rAHF-PFM is effective and safe in the treatment of children with hemophilia A. The study consists of 2 parts. Part 1 of the study is a phar...
AFSTYLA (antihemophilic factor [recombinant] single chain) is a novel B-domain truncated recombinant Factor VIII (rFVIII). For AFSTYLA, an approximate 50% discrepancy was observed between results of t...
An intact glomerular filtration barrier is essential for maintaining plasma albumin levels. However, the capacity of the proximal tubule to reabsorb filtered albumin and the subsequent fate of this pr...
The SH-group at Cys-34 of human serum albumin (HSA) is a unique and accessible functional group that can be exploited for efficient linkage of a maleimide containing cytotoxic drug derivative to album...
A sensitive method for the purification and determination of two protein adducts, organophosphorus (OP)-BChE and OP-albumin adducts, in a single sample using a simultaneous sample preparation method w...
Sulphonylurea drugs stimulate insulin secretion from pancreatic β-cells primarily by inhibiting ATP sensitive potassium (KATP) channels in the β-cell membrane. The effective sulphonylurea concentrat...
A hereditary deficiency of blood coagulation factor XI (also known as plasma thromboplastin antecedent or PTA or antihemophilic factor C) resulting in a systemic blood-clotting defect called hemophilia C or Rosenthal's syndrome, that may resemble classical hemophilia.
An azo dye used in blood volume and cardiac output measurement by the dye dilution method. It is very soluble, strongly bound to plasma albumin, and disappears very slowly.
Blood-coagulation factor VIII. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin.
A condition in which albumin level in blood (SERUM ALBUMIN) is below the normal range. Hypoalbuminemia may be due to decreased hepatic albumin synthesis, increased albumin catabolism, altered albumin distribution, or albumin loss through the urine (ALBUMINURIA).
Removal of plasma and replacement with various fluids, e.g., fresh frozen plasma, plasma protein fractions (PPF), albumin preparations, dextran solutions, saline. Used in treatment of autoimmune diseases, immune complex diseases, diseases of excess plasma factors, and other conditions.